Boehringer Ingelheim
About Boehringer Ingelheim
Boehringer Ingelheim is a global pharmaceuticals company headquartered in Ingelheim, Germany. With a workforce of over 53,000 employees, the company is dedicated to advancing health care through innovative solutions for both human and animal health. They focus on research and development to deliver high-quality medicines that improve the well-being of people and animals worldwide.
Recent News
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Novo's Double Departures: As GLP-1 Luminary Retires, an Obesity Leader Goes to Boehringer Ingelheim
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Boehringer Drug Scores in Rare Kidney Disease FSGS
Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data
CMS's Medicare Price Negotiations Start Round Three
Nine Biotech Companies that Could Revolutionize Obesity Treatments
A Deep Dive Into INN Proposed List 134
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Cipla Secures FDA Approval for Generic Nintedanib Capsules, Expanding U.S. IPF Portfolio
Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes
FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market
Biopharma Catalysts in Q2 2026 Signal High-Profile Approval Decisions and Rising Competition
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
Boehringer Ingelheim Introduces LENZELTA®: A New Vaccine Advancing Mastitis Prevention in Dairy Cows
Pig Liver Xenotransplant Shows Promise, but More Work Remains
Boehringer Ingelheim Gets an IBD Bispecific From Shanghai-Based Simcere
The Pink Pill: New Documentary Exposes the Long Battle to Bring Addyi — the First Libido Drug for Women — to Market
Will Cancer Drugmakers Ever Conquer P53?
Mansoor Amiji: Rare Gem and Modern-Day Polymath
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach
More Data Support Investigational Drug Combo for HIV Therapy
Why Ozempic Doesn’t Work for Everyone: Scientists Just Found a Hidden Reason
Boehringer Ingelheim and Zai Lab Team up for Dual DLL3 Therapy Study
2025 Novel Small Molecule FDA Drug Approvals
